Suppr超能文献

椎间盘的潜在生物治疗方法。

Potential biologic therapies for the intervertebral disc.

作者信息

Evans Christopher

机构信息

Center for Molecular Orthopaedics, Harvard Medical School, 221 Longwood Avenue, BLI-152, Boston, MA 02115, USA.

出版信息

J Bone Joint Surg Am. 2006 Apr;88 Suppl 2:95-8. doi: 10.2106/JBJS.E.01328.

Abstract

Biology offers several strategies for restoring the degenerating disc, including the use of recombinant or natural proteins that increase matrix accumulation and assembly, enhance the number of disc cells, or in other ways lead to restoration of the native healthy disc. Recombinant bone morphogenetic protein-7 (osteogenic protein-1) shows promise in this regard. Other growth factors, as well as cytokine antagonists such as the interleukin-1 receptor antagonist, are also good candidates. Because disc degeneration is a chronic, progressive disorder occurring over many years, it is likely that growth factors and other therapeutic proteins will need to be present in the disc for extended periods of time. The intradiscal injection of recombinant or natural proteins is unlikely to fulfill this requirement. In this scenario, the delivery of genes that encode the protein in question may provide a better delivery system. Kang and associates have pioneered this strategy, demonstrating the responsiveness of disc cells to in situ genetic modification. The success of protein and gene therapy requires the presence of an adequate number of responding cells. Disc degeneration is accompanied by a decline in cellularity. Restoring cell numbers could be achieved by either stimulating the division and inhibiting the death of endogenous cells or by introducing new cells into the disc. The latter strategy may be more successful, especially if the endogenous cells of a degenerating disc are unresponsive or otherwise abnormal. When pursuing this strategy, there are several important reasons why it is better to introduce progenitor cells than to attempt to harvest and reintroduce mature disc cells. Progenitor cells of the mesenchymal lineage, available from bone marrow, fat, and other convenient sources, could be useful. However, although the presumption exists that these types of cells can differentiate into disc cells, this has never been demonstrated. One impediment to confirming differentiation into a disc cell is our inability to identify these cells; there are no robust molecular, biochemical, or biologic markers. The serious study of disc-cell biology at this level would be most rewarding.

摘要

生物学提供了几种修复退变椎间盘的策略,包括使用重组蛋白或天然蛋白,这些蛋白可增加基质的积累和组装、增加椎间盘细胞数量,或以其他方式使椎间盘恢复到天然健康状态。重组骨形态发生蛋白-7(成骨蛋白-1)在这方面显示出前景。其他生长因子以及细胞因子拮抗剂,如白细胞介素-1受体拮抗剂,也是不错的选择。由于椎间盘退变是一种多年来发生的慢性、进行性疾病,生长因子和其他治疗性蛋白可能需要在椎间盘中长时间存在。经椎间盘内注射重组蛋白或天然蛋白不太可能满足这一要求。在这种情况下,递送编码相关蛋白的基因可能会提供更好的递送系统。Kang及其同事开创了这一策略,证明了椎间盘细胞对原位基因修饰的反应性。蛋白质和基因治疗的成功需要有足够数量的反应细胞。椎间盘退变伴随着细胞数量的减少。恢复细胞数量可以通过刺激内源性细胞的分裂并抑制其死亡,或者通过将新细胞引入椎间盘来实现。后一种策略可能更成功,特别是如果退变椎间盘中的内源性细胞无反应或存在其他异常情况。在采用这种策略时,引入祖细胞比试图收获并重新引入成熟椎间盘细胞更好,有几个重要原因。可从骨髓、脂肪和其他便利来源获取的间充质谱系祖细胞可能会有用。然而,尽管推测这些类型的细胞可以分化为椎间盘细胞,但这从未得到证实。确认分化为椎间盘细胞的一个障碍是我们无法识别这些细胞;没有强大的分子、生化或生物学标志物。在这个层面上对椎间盘细胞生物学进行认真研究将非常有意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验